TY - JOUR
T1 - HLA and KIR associations of cervical neoplasia
AU - Bao, Xiao
AU - Hanson, Aimee L.
AU - Madeleine, Margaret M.
AU - Wang, Sophia S.
AU - Schwartz, Stephen M.
AU - Newell, Felicity
AU - Pettersson-Kymmer, Ulrika
AU - Hemminki, Kari
AU - Tiews, Sven
AU - Steinberg, Winfried
AU - Rader, Janet S.
AU - Castro, Felipe
AU - Safaeian, Mahboobeh
AU - Franco, Eduardo L.
AU - Coutlée, François
AU - Ohlsson, Claes
AU - Cortes, Adrian
AU - Marshall, Mhairi
AU - Mukhopadhyay, Pamela
AU - Cremin, Katie
AU - Johnson, Lisa G.
AU - Garland, Suzanne M.
AU - Tabrizi, Sepehr N.
AU - Wentzensen, Nicolas
AU - Sitas, Freddy
AU - Trimble, Cornelia
AU - Little, Julian
AU - Cruickshank, Maggie
AU - Frazer, Ian H.
AU - Hildesheim, Allan
AU - Brown, Matthew A.
AU - Duncan, Emma L.
AU - Sun, Ying Pu
AU - Leo, Paul J.
N1 - Funding Information:
Financial support. This work was supported by the National Health and Medical Research Council, Australia (senior principal research fellowship to M. A. B. and grant 387701); the Australian Cancer Research Foundation; the National Cancer Institute, National Institutes of Health (grants P01CA042792 and R01CA112512); the Cancer Council New South Wales, Australia; the Canadian Institutes of Health Research (grant MOP-42532); Réseau sida et maladies infectieuses du Fonds de recherche du Québec – Santé; the Swedish Research Council; the Swedish Foundation for Strategic Research; the LUA-ALF (research grants via the University of Gothenburg and the University of Umeå); the Lundberg Foundation; the Torsten and Ragnar Söderberg’s Foundation; the Novo Nordisk Foundation; the European Commission (grant HEALTH-F2-2008-201865-GEFOS, BBMRI.se); the Swedish Society of Medicine; the Kempe-Foundation (grant JCK-1021); the Medical Faculty of Umeå University; the County Council of Västerbotten (grant Spjutspetsanslag VLL:159:33–2007); the Canada Research Chairs Program (tier 1 Canada research chair in human genome epidemiology to J. L.); and the Royal Women’s Hospital Clinical Research Foundation.
Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
PY - 2018/11/5
Y1 - 2018/11/5
N2 - Background. Cervical cancer is the fourth most common cancer in women, and we recently reported human leukocyte antigen (HLA) alleles showing strong associations with cervical neoplasia risk and protection. HLA ligands are recognized by killer immunoglobulin-like receptors (KIRs) expressed on a range of immune cell subsets, governing their proinflammatory activity. We hypothesized that the inheritance of particular HLA-KIR combinations would increase cervical neoplasia risk. Methods. Here, we used HLA and KIR dosages imputed from single-nucleotide polymorphism genotype data from 2143 cervical neoplasia cases and 13 858 healthy controls of European decent. Results. The following 4 novel HLA alleles were identified in association with cervical neoplasia, owing to their linkage disequilibrium with known cervical neoplasia-associated HLA-DRB1 alleles: HLA-DRB3*9901 (odds ratio [OR], 1.24; P = 2.49 × 10−9), HLA-DRB5*0101 (OR, 1.29; P = 2.26 × 10−8), HLA-DRB5*9901 (OR, 0.77; P = 1.90 × 10−9), and HLA-DRB3*0301 (OR, 0.63; P = 4.06 × 10−5). We also found that homozygosity of HLA-C1 group alleles is a protective factor for human papillomavirus type 16 (HPV16)-related cervical neoplasia (C1/C1; OR, 0.79; P = .005). This protective association was restricted to carriers of either KIR2DL2 (OR, 0.67; P = .00045) or KIR2DS2 (OR, 0.69; P = .0006). Conclusions. Our findings suggest that HLA-C1 group alleles play a role in protecting against HPV16-related cervical neoplasia, mainly through a KIR-mediated mechanism.
AB - Background. Cervical cancer is the fourth most common cancer in women, and we recently reported human leukocyte antigen (HLA) alleles showing strong associations with cervical neoplasia risk and protection. HLA ligands are recognized by killer immunoglobulin-like receptors (KIRs) expressed on a range of immune cell subsets, governing their proinflammatory activity. We hypothesized that the inheritance of particular HLA-KIR combinations would increase cervical neoplasia risk. Methods. Here, we used HLA and KIR dosages imputed from single-nucleotide polymorphism genotype data from 2143 cervical neoplasia cases and 13 858 healthy controls of European decent. Results. The following 4 novel HLA alleles were identified in association with cervical neoplasia, owing to their linkage disequilibrium with known cervical neoplasia-associated HLA-DRB1 alleles: HLA-DRB3*9901 (odds ratio [OR], 1.24; P = 2.49 × 10−9), HLA-DRB5*0101 (OR, 1.29; P = 2.26 × 10−8), HLA-DRB5*9901 (OR, 0.77; P = 1.90 × 10−9), and HLA-DRB3*0301 (OR, 0.63; P = 4.06 × 10−5). We also found that homozygosity of HLA-C1 group alleles is a protective factor for human papillomavirus type 16 (HPV16)-related cervical neoplasia (C1/C1; OR, 0.79; P = .005). This protective association was restricted to carriers of either KIR2DL2 (OR, 0.67; P = .00045) or KIR2DS2 (OR, 0.69; P = .0006). Conclusions. Our findings suggest that HLA-C1 group alleles play a role in protecting against HPV16-related cervical neoplasia, mainly through a KIR-mediated mechanism.
KW - Cervical neoplasia
KW - HPV16-related cervical neoplasia
KW - Human leukocyte antigens (HLA)
KW - Killer immunoglobulin-like receptors (KIRs)
UR - http://www.scopus.com/inward/record.url?scp=85056286117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056286117&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiy483
DO - 10.1093/infdis/jiy483
M3 - Article
C2 - 30099516
AN - SCOPUS:85056286117
SN - 0022-1899
VL - 218
SP - 2006
EP - 2015
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 12
ER -